of gliomas, at least in part, lead to the failure of traditional treatments. Therefore, understanding the particular mechanisms underlying this invasive behavior is vital for the identification of novel targets that might be used for prognostic, diagnostic, or therapeutic purposes and for the characterization of subgroups of patients who may preferentially respond to certain targeted therapies.
In mammals, the partitioning defective protein (Par) family includes MARK kinase (Pard1), Pard3, Pard4 (LKB1), Pard5 (14-3-3ζ), Pard6, and atypical protein kinase C (aPKC) and plays a major role in numerous aspects of cells biology including polarization, migration, invasion, and proliferation. 3 The Par complex (Pard3, Pard6, aPKC, and Cdc42) regulates various processes including the maintenance of asymmetrical cell divisions, apical-basal polarity and directional cell migration. 4 The
Par complex member Pard3 is a scaffold protein that includes a C-terminal domain, an N-terminal domain and three PDZ domains. The PDZ domains interact with proteins such as Pard6, phosphatase, and tensin homologue. 5 The N-terminal domain is critical for the apical localization and dimerization of Pard3. 6 The C-terminal domain interacts with aPKC to restrict its activity and with the Rac exchange factor T lymphoma invasion and metastasis inducing factor 1 to restrict its exchange activity. 7 The Rho/ROCK pathway plays a major role in many biologic processes by regulating a variety of proteins. RhoA (Ras homolog family member A) acts as a cancer suppressor gene and plays a significant role in tumor progression. 8 Previous findings indicate that the Rho/ROCK pathway is actively involved in the regulation of glioma cell death. 9 RhoA is also an important suppressor of EMT (Epithelial-mesenchymal transition) 10 ; the loss of RhoA is correlated with tumor grade and predicts a poor outcome in patient. 11 . Although RhoA is downregulated in some cancers, the regulation of RhoA protein expression is largely unclear. Previous studies have reported on the clinical significance of Pard3 in lung squamous cell carcinomas, 12 breast cancers, 7 renal cell carcinomas, and esophageal squamous cell carcinomas. 13 These studies showed that Pard3 is not only downregulated in these cancers but also a marker for poor prognosis and tumor aggressiveness, indicating that Pard3 plays a vital role in the progression of numerous tumor types. However, the role of Pard3 in cell migration and invasion, two key characteristics of malignant gliomas, remains unknown. In this study, we analyzed the effect of Pard3 on the migration of malignant glioma cells and found that Pard3 suppresses glioma cell invasion by regulating RhoA through aPKC/NF-κB signaling.
| MATERIAL AND METHODS

| Bioinformatics database
GBM gene expression (AgilentG4502A_07_1) date comes from The Cancer Genome Atlas (https://tcga-data.nci.nih.
gov/tcga/). We then used a number of Bioconductor packages to process the BAM files into gene count matrix 
| In vitro knockdown and overexpression
| CCK-8 assay
For the CCK-8 (cell counting kit-8) assay, cells were cultured in complete culture medium at a density of 6 × 10 3 /well in Statistical significance was tested using one-way ANOVA followed by Dunnett's tests for multiple comparison and two-tailed t-tests. **P < 0.01, ***P < 0.001. ANOVA, analysis of variance; HGG, high-grade glioma;
LGG, low-grade glioma; Pard3, partitioning defective protein 3 96-well plates. After treatment with CCK-8 (10 μL), the absorbance was measured at 450 nm using a microplate reader and the baseline reading was subtracted.
| Colony formation assay
For each cell line, 600 cells/well were plated in triplicate into six-well plates containing 3 ml of culture medium with 10% FBS. Cells were cultivated for two weeks at 37°C and 5% CO 2 , during which period the culture medium was not changed. Then, the cells were fixed with 4% formaldehyde and stained with crystal violet. Colonies with a diameter >2 mm were counted and photographed. All experiments were performed in triplicate.
| Western blotting
Cell lysates were separated by electrophoresis on a 12% SDS-PAGE gel at 120 V for 2 hours and then transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore).
The membrane was blocked with 5% fat-free milk in PBS for 2 hours. Next, the membranes were incubated with primary and secondary antibodies and visualized using a chemiluminescent reagent (Thermos).
| qRT-PCR
Total RNA was isolated from glioma samples using TRIZOL reagent (Invitrogen, USA). cDNA synthesis and real-time PCR were performed using the SYBR ® Premix Ex Taq ™ Kit (Takara, Japan). 18S rRNA was used as an internal control. The sequences of the Pard3 primers were as follows: forward, 5'-CAGACAGAACTACTAACTTCGCC-3'; reverse, 5'-ATGC CTCGGATGAAGAGTCCT-3'. The sequences of the RhoA primers were as follows: forward, 5'-AGCCTGTGGAAAG ACATGCTT-3'; reverse, 5'-TCAAACACTGTGGGCACAT AC-3'. Relative mRNA expression levels were normalized as described previously.
14,15 After approximately 4 weeks, the mice were sacrificed, and the tumors were extracted, weighed and fixed in formaldehyde solution. Humane endpoints were established in our study according to the relevant guidelines of AAALAC.
| Tumor xenograft model
| Immunohistochemical and immunofluorescence staining
Immunofluorescence (IF) staining was performed as described previously. 16 Cells were cultured in a 35-mm dish and fixed with 4% paraformaldehyde. After fixation, the cells were permeabilized with Triton X-100, blocked with 5% bovine serum albumin (BSA) in PBS for 1 hour at room temperature, incubated with anti-Pard3 (1:300) antibody in 0.3% BSA in PBS, and finally incubated with a Cy3-conjugated secondary antibody (1:100, Promoter, Wuhan, China) in 0.3% BSA in PBS. Fluorescence was visualized using a Laser Scanning Confocal Microscope (Olympus, Japan).
T A B L E 1 Association of Pard3 expression with clinicopathological characteristics in human glioma
Features
No.
Pard3
P-value Low High
Age (y) Immunohistochemistry and semiquantitative scoring techniques were performed as described previously. 17 Scores were defined as the cell staining intensity (0 = negative; 1 = weak; 2 = moderate; and 3 = strong) multiplied by the extent of positively stained cells (75%-100% = 4, 50%-74% = 3, 25%-49% = 2, 1%-24% = 1, 0% = 0), resulting in scores between 0 and 12.
| NF-κB luciferase reporter assays
The NF-κB luciferase reporter assay was performed as described previously. 18 Briefly, the NF-κB promoter was cloned into the (Invitrogen, USA). Then, 48 hours after transfection, cells were lyzed using 18 μL of passive lysis buffer. Next, a dualluciferase assay was performed using a dual luciferase reporter gene assay kit (Beyotime, Nanjing, China). Firefly luciferase values were normalized to Renilla luciferase values and the resulting ratios were used to express luciferase activities. All experiments were performed in triplicate. 
| EdU proliferation assay
| Statistical analysis
All the data are presented as the mean ± standard deviation from at least three independent experiments. The unpaired/ paired Student's t test was used to identify statistically significant data between two groups and one-way analysis of variance followed by Dunnett's multiple comparisons tests was used to identify statistically significant data between more than two groups both using the IBM SPSS Statistics 19. Survival analyses were evaluated using log-rank tests and Kaplan-Meier plots and Multivariate survival analyses were performed using a Cox regression model. P < 0.05 were considered statistically significant.
| RESULTS
| Bioinformatics Pard3 expression analysis demonstrates that Pard3 is often lost and correlates with poor prognosis in human gliomas
The genomic sequences of 25 normal brain tissue samples and 43 glioblastoma tissues were obtained from the glioblastoma whole gene expression map database of the Cancer and Tumor Gene Mapping (TCGA) Plan Database. We found that Pard3 expression was significantly lower in tumors compared to normal brains ( Figure 1A ). The expression of Pard3 in human gliomas of various grades was assessed by RT-PCR. We identified a significant difference in Pard3 gene expression in glioma cells of different grades ( Figure 1B ). Western blot analysis confirmed that Pard3 expression was typically decreased in higher-grade gliomas ( Figure 1C ). We then conducted immunohistochemical analyses to detect Pard3 expression levels in 49 human glioma samples. As shown in Figure 1D , the Pard3 immunostaining intensity was significantly different in human glioma samples of different grades. Quantification of this staining intensity further demonstrated that Pard3 protein expression was significantly reduced in high-grade gliomas ( Figure 1E ). We then examined the correlation of Pard3 expression with clinicopathological features in 49 glioma specimens with informative IHC date. Our results revealed that the reduction in Pard3 expression was significantly correlated with Karnofsky Performance Scale (KPS) score (P = 0.04) and recurrence (P = 0.01, Table 1 ), which is consistent with KPS as an independent predictor of survival. 19 As shown in Table 2 , low expression of Pard3 was related to a significantly increased risk of tumor recurrence in glioma patients (P < 0.01) compared to those with high Pard3 expression by univariate Cox regression analyses (Table 2) . Multivariate Cox regression analysis indicated that Pard3 could predict poor survival when Pard3 expression (P = 0.04), tumor grade (P = 0.045) and tumor recurrence (P < 0.01) were included ( Table 2) . These results verify a significant correlation of the expression of Pard3 with the prognosis of glioma. Furthermore, Kaplan-Meier analysis demonstrated that the reduction in Pard3 expression was significantly correlated with poorer DFS rates in glioma patients ( Figure 1F) . Multivariate Cox regression analysis demonstrated that the hazard ratio (HR) for DFS was higher (HR 1.88 95% CI 1.339-2.42, P = 0.0022) in tumors expressing high levels of Pard3 compared with tumors expressing low levels of Pard3.
| Knockdown of Pard3 promotes glioma cells proliferation, migration and invasion
First, we measured Pard3 expression by western blotting between human brain gliocyte cell lines and human brain glioma cell lines. The result shows that Pard3 is overexpressed in glioma cell lines compared with the human brain gliocyte cell lines ( Figure S1 ). We next knocked down Pard3 in U-87 and U-251 glioma cells using short hairpin RNAs. Knockdown efficiency was verified by qRT-PCR and Western blotting (Figure 2A,B) . We then used CCK-8, EdU, colony formation, and Transwell assays to test the effect of Pard3 on the proliferation, migration, and invasion of glioma cells. The results indicated that Pard3 silencing significantly promotes glioma cell proliferation, migration,s and invasion ( Figure 2C -G).
| Pard3 overexpression inhibits glioma cell proliferation, migration, and invasion
Next, we investigated whether Pard3 overexpression could suppress glioma cell proliferation, migration, and invasion. The Pard3 cDNA was cloned into pcDNA3.0 to construct overexpression plasmid pcDNA3.0-Pard3. The transfection efficiency was verified by both qRT-PCR and Western blotting ( Figure 3A,B) . Then, we used CCK-8, EdU, colony formation, and Transwell assays to assess the effects of Pard3 overexpression on the proliferation, migration, and invasion of glioma cell. The results indicated that Pard3 overexpression significantly inhibits glioma cell proliferation, migration, and invasion ( Figure 3C-G) . 
| RhoA is involved in Pard3-mediated glioma cell proliferation, migration and invasion
Previous studies have reported that RhoA proteins are involved in a variety of cellular processes and function through a number of different mechanisms. 20 Further, studies have reported that RhoA overexpression could suppress the proliferation and invasion of glioma cells. 21 Therefore,
we hypothesized that upregulation of Pard3 might promote the activation or expression of RhoA, thereby decreasing glioma cell proliferation and invasion. We examined the levels of GTP-bound (active) RhoA using Glutathione S transferase (GST) pull-down experiments and found that it was relatively unchanged. However, RhoA protein levels were markedly increased upon Pard3 overexpression ( Figure 4A ). To further test whether RhoA is involved in Pard3-mediated glioma cell proliferation and invasion, we used short hairpin RNAs (shRNAs) targeting RhoA in U-87 and U-251 cells ( Figure 4B ). RhoA silencing rescued the inhibitory effects of Pard3 overexpression on U-87 and U-251 cell proliferation ( Figure 4C ,D), colony formation ( Figure 4E ), migration ( Figure 4F ), and invasion ( Figure  4G ). These results indicate that Pard3 suppresses the migration and invasion of glioma cells by regulating RhoA protein expression.
| Activation of aPKC stimulates RhoA expression when Pard3 is overexpressed
Inhibition of the interaction between 14-3-3ζ and Pard3 could accelerate the release of aPKC from the Par/aPKC complex. 22 Therefore, we used gene transfection to verify the hypothesis that Pard3 may stimulate RhoA gene expression by activating aPKC signaling. First, we verified that Pard3 overexpression activates aPKC by detecting Thr-560 phosphorylation levels. aPKC is activated in U-87 cells following Pard3 overexpression ( Figure 5A ). Compared with the control group, cells in which PKCζ was silenced displayed reduced levels of RhoA, demonstrating that aPKCζ is essential for the promotion of RhoA expression ( Figure 5B ). We expressed wild-type RFP-labeled aPKCζ and observed that RhoA expression increased ( Figure 5C ). Similar results were observed in U-251 cells as well, indicating that this is a general mechanism in glioma cells ( Figure 5B ,C).
| aPKC activation increases RhoA through NF-κB signaling
NF-κB signaling can be affected following aPKC activation. 23 However, it is unclear whether these processes are involved in Pard3-mediated RhoA protein expression. aPKCζ communicates with aPKCι to activate the NF-κB signaling pathway, and NF-κB signaling activation could increase RhoA expression. Therefore, we performed the Cignal Finder Cancer 10-Pathway Reporter Kit to screen possibly involved signaling pathways during this process to find possible potential mechanism of Pard3-regulated glioma cell growth. The final result indicated that NF-κB signaling was markedly suppressed, whereas other signaling pathways were not notably affected by Pard3 knockdown in U-87 and U-251 cells ( Figure S2 ). To validate this result, we cocultured Pard3-overexpressing cells with two chemical inhibitors of the NF-κB signaling pathway: CAPE and JSH-23. JSH-23 inhibition efficiency in U-87 and U-251 cells was first verified by examining p65 expressing levels ( Figure 6A ). RhoA protein expression levels were attenuated by CAPE and JSH-23 in Pard3-overexpressing U-87 and U-251 cells ( Figure 6B ). Next, the activity of the NF-κB signaling pathway was measured following Pard3 overexpression. Pard3 overexpression resulted in a decrease in the expression of the IκBα subunit and an increase in the phosphorylation of IKK and p65 ( Figure 6C ). Furthermore, Pard3 overexpression in U-87 cells was accompanied by the migration of the p65 subunit to the nucleus. These effects could be rescued by the silencing of aPKCζ ( Figure 6C,D) . To verify the transcriptional activation of NF-κB, we transfected U-87 cells with an NF-κB luciferase reporter plasmid. Pard3 overexpression activated NF-κB, and this effect could be attenuated by aPKCζ silencing ( Figure 6E ). Finally, RhoA protein expression levels increased upon IκBα protein knockdown ( Figure 6F ). All of these results strongly indicate that aPKC activation increases RhoA through NF-κB signaling.
| Overexpression of Pard3 suppresses tumorigenesis in vivo
We then investigated whether Pard3 overexpression suppressed glioma cell tumor growth in vivo. U-87 and U-251 cells stably overexpressing Pard3 and with silenced RhoA were subcutaneously implanted into nude mice. After approximately 4 weeks, the mice were sacrificed, and the tumors were extracted and weighed ( Figure 7A ). IF staining for Ki-67 showed that Pard3 overexpression suppressed the expression of Ki-67 compared with the control group. However, RhoA knockdown rescued the Pard3 overexpression-mediated inhibition of Ki-67 ( Figure 7B ). Furthermore, IHC showed that the expression of Pard3 and RhoA in each group ( Figure 7C ). All of these results strongly indicate that Pard3 overexpression can suppress tumorigenesis in vivo.
F I G U R E 4 RhoA is involved in
Pard3-mediated glioma cell proliferation, migration, and invasion. A, Upregulation of Pard3 increased the total expression levels of RhoA. Levels of active RhoA were measured using a GST-RBD pull-down assay. Rhotekin-conjugated GST beads were used as the bait for capturing GTP- , total aPKCζ, RhoA-GTP, RhoA,and β-actin. C, U-87 and U-251 cells transfected with aPKCζ or Pard3 plasmids were collected, and the lysates were immunoblotted for P-aPKCζ T560 , total aPKCζ, RhoA-GTP, RhoA, and β-actin. aPKC, atypical protein kinase C; Pard3, partitioning defective protein 3; RhoA, Ras homolog family member A. *P < 0.05
| Model of Pard3-mediated regulation of
RhoA expression
When Pard3 is overexpressed, it activates aPKCζ, which phosphorylates IKK and IκBα. IκBα degradation liberates p65, allowing this protein to enter the nucleus and promote the transcription of RhoA. Increased RhoA protein levels inhibit glioma cell proliferation and invasion (Figure 8 ).
| DISCUSSION
Malignant glioma, the most common type of primary brain tumor in adults, is associated with disproportionate cancerrelated mortality and morbidity. 24 These tumors are highly aggressive, incurable malignancies, and exhibit poor clinical outcomes. Thus, it is urgent to explore novel and efficient molecular markers for the diagnosis and treatment of patients with gliomas. In recent years, many studies have reported that Pard3 is downregulated in various types of human cancers, including lung squamous cell carcinoma, 12 pancreatic cancer, 25 breast cancer 26 , and esophageal squamous cell carcinoma. 13 However, other studies have reported that Pard3 may act as an oncogene in multiple cancers, including prostate cancer, 27 squamous cell carcinomas 28 , and papillomas. 29 Loss of Pard3 can affect both proliferation and apoptosis in mammary epithelial cells. 30 It is still unclear whether Pard3 plays a suppressive or oncogenic role in glioma. In this study, we identified Pard3 as a novel tumor suppressor in glioma. First, the TCGA databases was used to demonstrate decreased Pard3 mRNA expression levels in glioma tissues, compared with adjacent normal brain tissues. In addition, data from clinical samples again confirm the low expression of Pard3 in high-grade gliomas by qRT-PCR, Western blotting and IHC. Our functional study demonstrated that Pard3 overexpression suppresses tumor cell proliferation, migration, invasion, and tumor formation in nude mice. Conversely, Pard3 silencing facilitated tumor cell proliferation, migration, and invasion. However, the molecular mechanisms underlying this suppressive function remain unclear. Based on our results, we hypothesize that the suppressive function of Pard3 stems, at least in part, from its role in promoting the activity of aPKC. Atypical PKC
F I G U R E 6 aPKC activation increases
RhoA through NF-κB signaling. A, U-87 and U-251 cells transfected with Pard3 plasmid and cultured with NF-κB inhibitors were collected, and the lysates were immunoblotted for P-p65, total p65 and β-actin. B, U-87 and U-251 cells transfected with Pard3 plasmid and cultured with NF-κB inhibitors were collected, and the lysates were immunoblotted for RhoA-GTP, RhoA, and β-actin. C, U-87 cells transfected with the indicated plasmid and cultured with NF-κB inhibitors were collected, and the lysates were immunoblotted for IκBα, phospho-IKKα/β, total IKKα, total IKKβ, phospho-p65, total p65, and β-actin. D, U-87 cells ectopically expressing Pard3 were immunostained for anti-p65 and stained with DAPI for DNA; Bars: 50 μm. E, The effect of Pard3 and aPKC on NF-κB transcriptional activity was evaluated using a reporter assay. F, U-87 cells transfected with siIκBα plasmid were collected, and the lysates were immunoblotted for RhoA-GTP, RhoA, and β-actin. aPKC, atypical protein kinase C; Pard3, partitioning defective protein 3; RhoA, Ras homolog family member A. **P < 0.01 | LI et aL.
F I G U R E 7
Overexpression of Pard3 suppresses tumorigenesis in vivo. A, Images of xenograft tumors from nude mice implanted with infected U-87 and U-251 cells. A1 and A2 shows the tumor volumes and weights. There were three mice in each group. B, Immunofluorescence staining for Ki-67 in tumors from each group. Bars: 50 μm. C, IHC showed that the expression of Pard3 and RhoA in each group. Statistical significance was tested using one-way ANOVA followed by Dunnett's tests for multiple comparison and two-tailed t-tests. **P < 0.01. ANOVA, analysis of variance; none, non infected cells; Pard3, partitioning defective protein 3; RhoA, Ras homolog family member A isoforms (aPKCζ) have been demonstrated to be involved in migration in many cancers. 31 In human glioblastoma cells, it has been shown that reduction in aPKCζ inhibits tumor cell migration and invasion. 32 These reports are consistent with our data, which indicate that Pard3 downregulation accelerates the migration of glioma cells. Atypical protein kinase C/NF-κB signaling also plays a vital role in EMT, which induces tumor proliferation, migration, and invasion. 33 Previous studies have reported that AKT can facilitate the nuclear entry of NF-κB (p-P65), which can then function to increase Snail and Slug expression and thus accelerate EMT. 34 The exploration of RhoA was based on biological database predictions (such as String, PPI, etc), as well as screening of downstream proteins by Western blotting and PCR after Pard3 knockdown or overexpression. The PPI was constructed and the module analysis was performed using STRING and Cytoscape. Of course, our research group has studied this protein for many years. In this study, we found that aPKC can liberate NF-κB (p-P65), allowing it to enter the nucleus and thus upregulate RhoA expression to suppress glioma cells proliferation, migration, and invasion. Taken together, our results indicate that Pard3 overexpression suppresses glioma cell proliferation, invasion, migration in vitro and tumor growth in vivo. Our results demonstrate a novel mechanism whereby Pard3 modulates the protein levels, subcellular localization and transcriptional activity of RhoA by regulating aPKC/NF-κB signaling. The newly identified Pard3/RhoA/NF-κB pathway may help us to further illuminate the complicated molecular mechanisms of Par complexes and presents a novel strategy for diagnosing and therapy with glioma.
